Amedeo Smart

Free Medical Literature Service

 

Amedeo

Multiple Sclerosis
  Free Subscription

Articles published in
J Neurol
    June 2023
  1. HOLTZER R, Choi J, Motl RW, Foley FW, et al
    Individual reserve in aging and neurological disease.
    J Neurol. 2023;270:3179-3191.
    >> Share

    May 2023
  2. AZZIMONTI M, Preziosa P, Pagani E, Valsasina P, et al
    Functional and structural brain MRI changes associated with cognitive worsening in multiple sclerosis: a 3-year longitudinal study.
    J Neurol. 2023 May 18. doi: 10.1007/s00415-023-11778.
    >> Share

  3. ZANETTA C, Rocca MA, Meani A, Martinelli V, et al
    Correction to: Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
    J Neurol. 2023 May 17. doi: 10.1007/s00415-023-11772.
    >> Share

  4. MUNOZ-VENDRELL A, Arroyo-Pereiro P, Leon I, Bau L, et al
    Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment.
    J Neurol. 2023;270:2559-2566.
    >> Share

    April 2023
  5. KREMMYDA O, Feil K, Bardins S, Strupp M, et al
    Acetyl-DL-leucine in combination with memantine improves acquired pendular nystagmus caused by multiple sclerosis: a case report.
    J Neurol. 2023 Apr 27. doi: 10.1007/s00415-023-11730.
    >> Share

  6. VAN DAM M, de Jong BA, Willemse EAJ, Nauta IM, et al
    A multimodal marker for cognitive functioning in multiple sclerosis: the role of NfL, GFAP and conventional MRI in predicting cognitive functioning in a prospective clinical cohort.
    J Neurol. 2023 Apr 27. doi: 10.1007/s00415-023-11676.
    >> Share

  7. MARGONI M, Pagani E, Preziosa P, Gueye M, et al
    Unraveling the heterogeneous pathological substrates of relapse-onset multiple sclerosis: a multiparametric voxel-wise 3 T MRI study.
    J Neurol. 2023 Apr 24. doi: 10.1007/s00415-023-11736.
    >> Share

  8. KOUTSOURAKI E, Theodoros K, Eleni G, Marianna K, et al
    Autonomic nervous system disorders in multiple sclerosis.
    J Neurol. 2023 Apr 21. doi: 10.1007/s00415-023-11725.
    >> Share

  9. MONSCHEIN T, Dekany S, Zrzavy T, Ponleitner M, et al
    Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).
    J Neurol. 2023 Apr 19. doi: 10.1007/s00415-023-11686.
    >> Share

  10. GANAPATHY SUBRAMANIAN R, Zivadinov R, Bergsland N, Dwyer MG, et al
    Multiple sclerosis optic neuritis and trans-synaptic pathology on cortical thinning in people with multiple sclerosis.
    J Neurol. 2023 Apr 17. doi: 10.1007/s00415-023-11709.
    >> Share

  11. YEO T, Siew RWE, Gulam MY, Tye JSN, et al
    COVID-19 infection after SARS-CoV-2 mRNA vaccination in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD patients during the Omicron subvariant BA.1/2 wave in Singapore.
    J Neurol. 2023 Apr 7:1-9. doi: 10.1007/s00415-023-11692.
    >> Share

  12. ZANETTA C, Rocca MA, Meani A, Martinelli V, et al
    Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
    J Neurol. 2023 Apr 7:1-12. doi: 10.1007/s00415-023-11700.
    >> Share

  13. VRENKEN H, Battaglini M, de Vos ML, Nagtegaal GJ, et al
    Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon beta-1a.
    J Neurol. 2023;270:2271-2282.
    >> Share

  14. LEHTO J, Sucksdorff M, Nylund M, Raitanen R, et al
    PET-measurable innate immune cell activation reduction in chronic active lesions in PPMS brain after rituximab treatment: a case report.
    J Neurol. 2023;270:2329-2332.
    >> Share

  15. ASTBURY L, Kalra S, Tanasescu R, Constantinescu CS, et al
    CSF lymphocytic pleocytosis does not predict a less favourable long-term prognosis in MS.
    J Neurol. 2023;270:2042-2047.
    >> Share

    March 2023
  16. PLESS S, Woelfle T, Naegelin Y, Lorscheider J, et al
    Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study.
    J Neurol. 2023 Mar 23. doi: 10.1007/s00415-023-11671.
    >> Share

  17. TORRES P, Sancho-Saldana A, Gil Sanchez A, Peralta S, et al
    A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
    J Neurol. 2023 Mar 18:1-12. doi: 10.1007/s00415-023-11575.
    >> Share

  18. ROMANO F, Motl RW, Valsasina P, Amato MP, et al
    Abnormal thalamic functional connectivity correlates with cardiorespiratory fitness and physical activity in progressive multiple sclerosis.
    J Neurol. 2023 Mar 18. doi: 10.1007/s00415-023-11664.
    >> Share

  19. DE ROSA AP, Esposito F, Valsasina P, d'Ambrosio A, et al
    Correction to: Resting-state functional MRI in multicenter studies on multiple sclerosis: a report on raw data quality and functional connectivity features from the Italian Neuroimaging Network Initiative.
    J Neurol. 2023 Mar 13. doi: 10.1007/s00415-023-11646.
    >> Share

  20. MOGAVERO MP, Lanza G, Bruni O, DelRosso LM, et al
    Sleep counts! Role and impact of sleep in the multimodal management of multiple sclerosis.
    J Neurol. 2023 Mar 11. doi: 10.1007/s00415-023-11655.
    >> Share

  21. VELDKAMP R, D'hooge M, Sandroff BM, DeLuca J, et al
    Profiling cognitive-motor interference in a large sample of persons with progressive multiple sclerosis and impaired processing speed: results from the CogEx study.
    J Neurol. 2023 Mar 7. doi: 10.1007/s00415-023-11636.
    >> Share

  22. LI G, You Q, Hou X, Zhang S, et al
    The effect of exercise on cognitive function in people with multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials.
    J Neurol. 2023 Mar 2. doi: 10.1007/s00415-023-11649.
    >> Share

  23. GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
    Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing-remitting multiple sclerosis in Austria.
    J Neurol. 2023 Mar 2. doi: 10.1007/s00415-023-11644.
    >> Share

  24. BARLETTA VT, Herranz E, Treaba CA, Mehndiratta A, et al
    In vivo characterization of microglia and myelin relation in multiple sclerosis by combined (11)C-PBR28 PET and synthetic MRI.
    J Neurol. 2023 Mar 2. doi: 10.1007/s00415-023-11621.
    >> Share

  25. DIETMANN AS, Kruse N, Stork L, Gloth M, et al
    Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histological-serological correlative study.
    J Neurol. 2023;270:1416-1429.
    >> Share

    February 2023
  26. BAETGE SJ, Filser M, Renner A, Raithel LM, et al
    Supporting brain health in multiple sclerosis: exploring the potential of neuroeducation combined with practical mindfulness exercises in the management of neuropsychological symptoms.
    J Neurol. 2023 Feb 25:1-14. doi: 10.1007/s00415-023-11616.
    >> Share

  27. MONTINI F, Nozzolillo A, Rancoita PMV, Zanetta C, et al
    Modifiable risk factors of COVID-19 in patients with multiple sclerosis: a single-centre case-control study.
    J Neurol. 2023 Feb 16:1-8. doi: 10.1007/s00415-023-11618.
    >> Share

  28. SWINNEN S, De Wit D, Van Cleemput L, Cassiman C, et al
    Optical coherence tomography as a prognostic tool for disability progression in MS: a systematic review.
    J Neurol. 2023;270:1178-1186.
    >> Share

  29. HUANG L, Wang Y, Zhang R
    Retina thickness in clinically affected and unaffected eyes in patients with aquaporin-4 immunoglobulin G antibody seropositive neuromyelitis optica spectrum disorders: a systematic review and meta-analysis.
    J Neurol. 2023;270:759-768.
    >> Share

  30. GERNERT JA, Wicklein R, Hemmer B, Kumpfel T, et al
    Peripapillary hyper-reflective ovoid mass-like structures (PHOMS) in AQP4-IgG-positive neuromyelitis optica spectrum disease (NMOSD) and MOG-IgG-associated disease (MOGAD).
    J Neurol. 2023;270:1135-1140.
    >> Share

  31. MAGRO G, Barone S, Tosto F, De Martino A, et al
    Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic.
    J Neurol. 2023;270:595-600.
    >> Share

    January 2023
  32. CAGOL A, Fuertes NC, Stoessel M, Barakovic M, et al
    Optical coherence tomography reflects clinically relevant gray matter damage in patients with multiple sclerosis.
    J Neurol. 2023 Jan 10. doi: 10.1007/s00415-022-11535.
    >> Share

  33. DAVION JB, Jougleux C, Lopes R, Leclerc X, et al
    Relation between retina, cognition and brain volumes in MS: a consequence of asymptomatic optic nerve lesions.
    J Neurol. 2023;270:240-249.
    >> Share

    December 2022
  34. PENNINGTON P, Weinstock-Guttman B, Kolb C, Jakimovski D, et al
    Correction to: Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives.
    J Neurol. 2022 Dec 27. doi: 10.1007/s00415-022-11540.
    >> Share

  35. LOONSTRA FC, Falize KF, de Ruiter LRJ, Schoonheim MM, et al
    Adipokines in multiple sclerosis patients are related to clinical and radiological measures.
    J Neurol. 2022 Dec 23. doi: 10.1007/s00415-022-11519.
    >> Share

  36. SEN MK, Hossain MJ, Mahns DA, Brew BJ, et al
    Validity of serum neurofilament light chain as a prognostic biomarker of disease activity in multiple sclerosis.
    J Neurol. 2022 Dec 15. doi: 10.1007/s00415-022-11507.
    >> Share

  37. ALBERGONI M, Storelli L, Preziosa P, Rocca MA, et al
    The insula modulates the effects of aerobic training on cardiovascular function and ambulation in multiple sclerosis.
    J Neurol. 2022 Dec 12:1-10. doi: 10.1007/s00415-022-11513.
    >> Share

  38. GANZETTI M, Graves JS, Holm SP, Dondelinger F, et al
    Neural correlates of digital measures shown by structural MRI: a post-hoc analysis of a smartphone-based remote assessment feasibility study in multiple sclerosis.
    J Neurol. 2022 Dec 5. doi: 10.1007/s00415-022-11494.
    >> Share

  39. MOCCIA M, Affinito G, Berera G, Marrazzo G, et al
    Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy.
    J Neurol. 2022;269:6504-6511.
    >> Share

  40. PAKEERATHAN T, Havla J, Schwake C, Salmen A, et al
    Characteristic retinal atrophy pattern allows differentiation between pediatric MOGAD and MS after a single optic neuritis episode.
    J Neurol. 2022;269:6366-6376.
    >> Share

    November 2022
  41. SIMPSON R, Posa S, Bruno T, Simpson S, et al
    Conceptualization, use, and outcomes associated with compassion in the care of people with multiple sclerosis: a scoping review.
    J Neurol. 2022 Nov 29. doi: 10.1007/s00415-022-11497.
    >> Share

  42. PREZIOSA P, Rocca MA, Pagani E, Valsasina P, et al
    Structural and functional magnetic resonance imaging correlates of fatigue and dual-task performance in progressive multiple sclerosis.
    J Neurol. 2022 Nov 27. doi: 10.1007/s00415-022-11486.
    >> Share

  43. FILIPPI M, Preziosa P, Arnold DL, Barkhof F, et al
    Present and future of the diagnostic work-up of multiple sclerosis: the imaging perspective.
    J Neurol. 2022 Nov 24. doi: 10.1007/s00415-022-11488.
    >> Share

  44. MIRMOSAYYEB O, Zivadinov R, Weinstock-Guttman B, Benedict RHB, et al
    Optical coherence tomography (OCT) measurements and cognitive performance in multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2022 Nov 17. pii: 10.1007/s00415-022-11449.
    >> Share

  45. PENNINGTON P, Weinstock-Guttman B, Kolb C, Jakimovski D, et al
    Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives.
    J Neurol. 2022 Nov 14. pii: 10.1007/s00415-022-11405.
    >> Share

  46. GALPERIN I, Mirelman A, Schmitz-Hubsch T, Hsieh KL, et al
    Treadmill training with virtual reality to enhance gait and cognitive function among people with multiple sclerosis: a randomized controlled trial.
    J Neurol. 2022 Nov 11. pii: 10.1007/s00415-022-11469.
    >> Share

  47. DE ROSA AP, Esposito F, Valsasina P, d'Ambrosio A, et al
    Resting-state functional MRI in multicenter studies on multiple sclerosis: a report on raw data quality and functional connectivity features from the Italian Neuroimaging Network Initiative.
    J Neurol. 2022 Nov 9. pii: 10.1007/s00415-022-11479.
    >> Share

  48. SIMPSON R, Posa S, Langer L, Bruno T, et al
    A systematic review and meta-analysis exploring the efficacy of mindfulness-based interventions on quality of life in people with multiple sclerosis.
    J Neurol. 2022 Nov 9. pii: 10.1007/s00415-022-11451.
    >> Share

  49. NIINO M, Fukumoto S, Okuno T, Sanjo N, et al
    Health-related quality of life in Japanese patients with multiple sclerosis.
    J Neurol. 2022 Nov 5. pii: 10.1007/s00415-022-11453.
    >> Share

  50. KURI A, Vickaryous N, Awad A, Jacobs BM, et al
    Vitamin D genetic risk scores in multiple sclerosis.
    J Neurol. 2022 Nov 5. pii: 10.1007/s00415-022-11466.
    >> Share

    October 2022
  51. OMARY R, Bockisch CJ, De Vere-Tyndall A, Pazahr S, et al
    Lesion follows function: video-oculography compared with MRI to diagnose internuclear ophthalmoplegia in patients with multiple sclerosis.
    J Neurol. 2022 Oct 31. pii: 10.1007/s00415-022-11428.
    >> Share

  52. WUSCHEK A, Bussas M, El Husseini M, Harabacz L, et al
    Somatosensory evoked potentials and magnetic resonance imaging of the central nervous system in early multiple sclerosis.
    J Neurol. 2022 Oct 7. pii: 10.1007/s00415-022-11407.
    >> Share

  53. PREZIOSA P, Pagani E, Meani A, Marchesi O, et al
    NODDI, diffusion tensor microstructural abnormalities and atrophy of brain white matter and gray matter contribute to cognitive impairment in multiple sclerosis.
    J Neurol. 2022 Oct 6. pii: 10.1007/s00415-022-11415.
    >> Share

  54. KOCH MW, Mostert J, Repovic P, Bowen JD, et al
    The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset.
    J Neurol. 2022;269:5319-5327.
    >> Share

    September 2022
  55. MARGONI M, Pagani E, Preziosa P, Palombo M, et al
    In vivo quantification of brain soma and neurite density abnormalities in multiple sclerosis.
    J Neurol. 2022 Sep 24. pii: 10.1007/s00415-022-11386.
    >> Share

  56. PAGANI E, Storelli L, Pantano P, Petsas N, et al
    Multicenter data harmonization for regional brain atrophy and application in multiple sclerosis.
    J Neurol. 2022 Sep 24. pii: 10.1007/s00415-022-11387.
    >> Share

  57. FILIPPI M, Amato MP, Centonze D, Gallo P, et al
    Correction to: Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion.
    J Neurol. 2022 Sep 22. pii: 10.1007/s00415-022-11385.
    >> Share

  58. FILSER M, Buchner A, Fink GR, Gold SM, et al
    The manifestation of affective symptoms in multiple sclerosis and discussion of the currently available diagnostic assessment tools.
    J Neurol. 2022 Sep 21. pii: 10.1007/s00415-022-11359.
    >> Share

  59. CHAPPUIS M, Rousseau C, Bajeux E, Wiertlewski S, et al
    Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis.
    J Neurol. 2022 Sep 16. pii: 10.1007/s00415-022-11341.
    >> Share

  60. NICOLAS P, Marion-Moffet H, Gossez M, Vukusic S, et al
    Anti-SARS-CoV-2 humoral and cellular responses in multiple sclerosis patients treated with anti-CD20 monoclonal antibodies.
    J Neurol. 2022 Sep 12. pii: 10.1007/s00415-022-11353.
    >> Share

  61. CAPASSO N, Palladino R, Cerbone V, Spiezia AL, et al
    Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study.
    J Neurol. 2022 Sep 1. pii: 10.1007/s00415-022-11350.
    >> Share

    August 2022
  62. WOELFLE T, Pless S, Reyes O, Wiencierz A, et al
    Reliability and acceptance of dreaMS, a software application for people with multiple sclerosis: a feasibility study.
    J Neurol. 2022 Aug 30. pii: 10.1007/s00415-022-11306.
    >> Share

  63. FEINSTEIN A, Amato MP, Brichetto G, Chataway J, et al
    The late onset of emotional distress in people with progressive multiple sclerosis during the Covid-19 pandemic: longitudinal findings from the CogEx study.
    J Neurol. 2022 Aug 8. pii: 10.1007/s00415-022-11295.
    >> Share

  64. KREFT KL, Robertson NP
    Innovative biomarkers to predict unfavourable outcomes after initiating multiple sclerosis treatment.
    J Neurol. 2022 Aug 1. pii: 10.1007/s00415-022-11300.
    >> Share

    July 2022
  65. CAPUANO R, Altieri M, Conte M, Bisecco A, et al
    Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod.
    J Neurol. 2022 Jul 26. pii: 10.1007/s00415-022-11296.
    >> Share

  66. MUNOZ-JURADO A, Escribano BM, Aguera E, Caballero-Villarraso J, et al
    SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19.
    J Neurol. 2022 Jul 5. pii: 10.1007/s00415-022-11237.
    >> Share

  67. EID K, Torkildsen O, Aarseth J, Celius EG, et al
    Abuse and revictimization in adulthood in multiple sclerosis: a cross-sectional study during pregnancy.
    J Neurol. 2022 Jul 3. pii: 10.1007/s00415-022-11249.
    >> Share

  68. ALCALA C, Cubas L, Carratala S, Gascon F, et al
    NFL during acute spinal cord lesions in MS: a hurdle for the detection of inflammatory activity.
    J Neurol. 2022;269:3495-3500.
    >> Share

    June 2022
  69. CANNIZZARO M, Ferre L, Clarelli F, Giordano A, et al
    Early use of fingolimod is associated with better clinical outcomes in relapsing-remitting multiple sclerosis patients.
    J Neurol. 2022 Jun 27. pii: 10.1007/s00415-022-11227.
    >> Share

  70. SOROSINA M, Barizzone N, Clarelli F, Anand S, et al
    Correction to: A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility.
    J Neurol. 2022 Jun 25. pii: 10.1007/s00415-022-11216.
    >> Share

  71. LEGUY S, Lefort M, Lescot L, Michaud A, et al
    COPP-MS: COrticosteroids during the Post-Partum in relapsing Multiple Sclerosis patients.
    J Neurol. 2022 Jun 23. pii: 10.1007/s00415-022-11215.
    >> Share

  72. SANDROFF BM, Motl RW, Roman CAF, Wylie GR, et al
    Thalamic atrophy moderates associations among aerobic fitness, cognitive processing speed, and walking endurance in persons with multiple sclerosis.
    J Neurol. 2022 Jun 19. pii: 10.1007/s00415-022-11205.
    >> Share

  73. DORCET G, Migne H, Biotti D, Bost C, et al
    Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression.
    J Neurol. 2022 Jun 2. pii: 10.1007/s00415-022-11197.
    >> Share

  74. ZIEMSSEN T, Lang M, Schmidt S, Albrecht H, et al
    Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.
    J Neurol. 2022;269:3276-3285.
    >> Share

  75. DI SABATINO E, Gaetani L, Sperandei S, Fiacca A, et al
    The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI.
    J Neurol. 2022;269:3129-3135.
    >> Share

  76. MISCIOSCIA A, Puthenparampil M, Miante S, Pengo M, et al
    Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis.
    J Neurol. 2022 Jun 1. pii: 10.1007/s00415-022-11183.
    >> Share

    May 2022
  77. HRASTELJ J, Robertson NP
    A role for the Epstein-Barr virus in multiple sclerosis aetiology?
    J Neurol. 2022 May 31. pii: 10.1007/s00415-022-11177.
    >> Share

  78. GOLD R, Piani-Meier D, Kappos L, Bar-Or A, et al
    Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
    J Neurol. 2022 May 31. pii: 10.1007/s00415-022-11166.
    >> Share

  79. WILLISON AG, Ruck T, Lenz G, Hartung HP, et al
    Correction to: The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.
    J Neurol. 2022 May 24. pii: 10.1007/s00415-022-11158.
    >> Share

  80. FILIPPI M, Amato MP, Centonze D, Gallo P, et al
    Early use of high-efficacy diseasemodifying therapies makes the difference in people with multiple sclerosis: an expert opinion.
    J Neurol. 2022 May 24. pii: 10.1007/s00415-022-11193.
    >> Share

  81. BATTAGLIA MA, Bezzini D, Cecchini I, Cordioli C, et al
    Patients with multiple sclerosis: a burden and cost of illness study.
    J Neurol. 2022 May 23. pii: 10.1007/s00415-022-11169.
    >> Share

  82. SOROSINA M, Barizzone N, Clarelli F, Anand S, et al
    A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility.
    J Neurol. 2022 May 12. pii: 10.1007/s00415-022-11109.
    >> Share

  83. HONE L, Jacobs BM, Marshall C, Giovannoni G, et al
    Age-specific effects of childhood body mass index on multiple sclerosis risk.
    J Neurol. 2022 May 9. pii: 10.1007/s00415-022-11161.
    >> Share

  84. SPARASCI D, Gobbi C, Castelnovo A, Riccitelli GC, et al
    Fatigue, sleepiness and depression in multiple sclerosis: defining the overlaps for a better phenotyping.
    J Neurol. 2022 May 4. pii: 10.1007/s00415-022-11143.
    >> Share

  85. KIM H, Fraser S
    Neural correlates of dual-task walking in people with central neurological disorders: a systematic review.
    J Neurol. 2022;269:2378-2402.
    >> Share

    April 2022
  86. HVID LG, Stenager E, Dalgas U
    Objectively assessed physiological, physical, and cognitive function along with patient-reported outcomes during the first 2 years of Alemtuzumab treatment in multiple sclerosis: a prospective observational study.
    J Neurol. 2022 Apr 28. pii: 10.1007/s00415-022-11134.
    >> Share

  87. EINSIEDLER M, Kremer L, Fleury M, Collongues N, et al
    Anti-CD20 immunotherapy in progressive multiple sclerosis: 2-year real-world follow-up of 108 patients.
    J Neurol. 2022 Apr 17. pii: 10.1007/s00415-022-11124.
    >> Share

  88. DUBBIOSO R, Bove M, Boccia D, D'Ambrosio V, et al
    Neurophysiological and behavioural correlates of ocrelizumab therapy on manual dexterity in patients with primary progressive multiple sclerosis.
    J Neurol. 2022 Apr 13. pii: 10.1007/s00415-022-11114.
    >> Share

  89. ZHANG Y, Yin H, Zhang D, Xu Y, et al
    Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study.
    J Neurol. 2022 Apr 11. pii: 10.1007/s00415-022-11118.
    >> Share

  90. WILLISON AG, Ruck T, Lenz G, Hartung HP, et al
    The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.
    J Neurol. 2022 Apr 11. pii: 10.1007/s00415-022-11063.
    >> Share

  91. STORELLI L, Pagani E, Meani A, Preziosa P, et al
    Advanced diffusion-weighted imaging models better characterize white matter neurodegeneration and clinical outcomes in multiple sclerosis.
    J Neurol. 2022 Apr 10. pii: 10.1007/s00415-022-11104.
    >> Share

  92. CAROLUS K, Fuchs TA, Bergsland N, Ramasamy D, et al
    Time course of lesion-induced atrophy in multiple sclerosis.
    J Neurol. 2022 Apr 8. pii: 10.1007/s00415-022-11094.
    >> Share

  93. MOOG TM, McCreary M, Wilson A, Stanley T, et al
    Direction and magnitude of displacement differ between slowly expanding and non-expanding multiple sclerosis lesions as compared to small vessel disease.
    J Neurol. 2022 Apr 5. pii: 10.1007/s00415-022-11089.
    >> Share

  94. BUONOMO AR, Viceconte G, Calabrese M, De Luca G, et al
    Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.
    J Neurol. 2022 Apr 4. pii: 10.1007/s00415-022-11066.
    >> Share

  95. VANDEBERGH M, Degryse N, Dubois B, Goris A, et al
    Environmental risk factors in multiple sclerosis: bridging Mendelian randomization and observational studies.
    J Neurol. 2022 Apr 2. pii: 10.1007/s00415-022-11072.
    >> Share

  96. FEINSTEIN A, Amato MP, Brichetto G, Chataway J, et al
    The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experience.
    J Neurol. 2022;269:1758-1763.
    >> Share

  97. ROJAS JI, Pappolla A, Blaya P, Marrodan M, et al
    Accumulative risk of clinical event in high-risk radiologically isolated syndrome in Argentina: data from the nationwide registry RelevarEM.
    J Neurol. 2022;269:2073-2079.
    >> Share

  98. ABBOUD H, Salazar-Camelo A, George N, Planchon SM, et al
    Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders.
    J Neurol. 2022;269:1786-1801.
    >> Share

    March 2022
  99. DEANA C, Bagatto D, Battezzi A, Pecori D, et al
    Disseminated nocardiosis after cladribine treatment for relapsing remitting multiple sclerosis: a case report.
    J Neurol. 2022 Mar 30. pii: 10.1007/s00415-022-11097.
    >> Share

  100. BISECCO A, Fornasiero A, Bianco A, Cortese A, et al
    Correction to: Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study.
    J Neurol. 2022 Mar 27. pii: 10.1007/s00415-022-11083.
    >> Share

  101. WENZEL N, Wittayer M, Weber CE, Schirmer L, et al
    MRI predictors for the conversion from contrast-enhancing to iron rim multiple sclerosis lesions.
    J Neurol. 2022 Mar 25. pii: 10.1007/s00415-022-11082.
    >> Share

  102. ALLMAN M, Tallantyre E, Robertson NP
    Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies.
    J Neurol. 2022 Mar 14. pii: 10.1007/s00415-022-11053.
    >> Share

  103. MISTRI D, Cacciaguerra L, Storelli L, Meani A, et al
    The association between cognition and motor performance is beyond structural damage in relapsing-remitting multiple sclerosis.
    J Neurol. 2022 Mar 12. pii: 10.1007/s00415-022-11044.
    >> Share

  104. MARIOTTINI A, Bertozzi A, Marchi L, Di Cristinzi M, et al
    Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis.
    J Neurol. 2022 Mar 3. pii: 10.1007/s00415-022-11003.
    >> Share

  105. ACHIRON A, Mandel M, Gurevich M, Dreyer-Alster S, et al
    Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod.
    J Neurol. 2022 Mar 2. pii: 10.1007/s00415-022-11030.
    >> Share

  106. KANINIA S, Edey AJ, Maskell NA, Rice CM, et al
    Natalizumab-induced pneumonitis.
    J Neurol. 2022;269:1688-1690.
    >> Share

  107. KOCH MW, Mostert J, Repovic P, Bowen JD, et al
    Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial dataset.
    J Neurol. 2022;269:1663-1669.
    >> Share

  108. BONACCHI R, Meani A, Pagani E, Marchesi O, et al
    The role of cerebellar damage in explaining disability and cognition in multiple sclerosis phenotypes: a multiparametric MRI study.
    J Neurol. 2022 Mar 1. pii: 10.1007/s00415-022-11021.
    >> Share

    February 2022
  109. COBO-CALVO A, Zabalza A, Rio J, Arrambide G, et al
    Correction to: Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.
    J Neurol. 2022 Feb 22. pii: 10.1007/s00415-022-11019.
    >> Share

  110. BERG-HANSEN P, Moen SM, Austeng A, Gonzales V, et al
    Sensor-based gait analyses of the six-minute walk test identify qualitative improvement in gait parameters of people with multiple sclerosis after rehabilitation.
    J Neurol. 2022 Feb 15. pii: 10.1007/s00415-022-10998.
    >> Share

  111. RICCARDO BA, Giulio V, Massimiliano C, Giovanna L, et al
    Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.
    J Neurol. 2022 Feb 14. pii: 10.1007/s00415-022-11009.
    >> Share

  112. CHIARAVALLOTI ND, Costa SL, Moore NB, Costanza K, et al
    The efficacy of speed of processing training for improving processing speed in individuals with multiple sclerosis: a randomized clinical trial.
    J Neurol. 2022 Feb 12. pii: 10.1007/s00415-022-10980.
    >> Share

  113. ALCALA C, Quintanilla-Bordas C, Gascon F, Sempere AP, et al
    Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.
    J Neurol. 2022 Feb 2. pii: 10.1007/s00415-022-10989.
    >> Share

  114. BUKHARI W, Khalilidehkordi E, Mason DF, Barnett MH, et al
    NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand.
    J Neurol. 2022;269:836-845.
    >> Share

  115. LANDI D, Signori A, Cellerino M, Fenu G, et al
    What happens after fingolimod discontinuation? A multicentre real-life experience.
    J Neurol. 2022;269:796-804.
    >> Share

    January 2022
  116. VIRGILIO E, Vecchio D, Crespi I, Puricelli C, et al
    Cerebrospinal fluid biomarkers and cognitive functions at multiple sclerosis diagnosis.
    J Neurol. 2022 Jan 28. pii: 10.1007/s00415-021-10945.
    >> Share

  117. PROSCHINGER S, Kuhwand P, Rademacher A, Walzik D, et al
    Fitness, physical activity, and exercise in multiple sclerosis: a systematic review on current evidence for interactions with disease activity and progression.
    J Neurol. 2022 Jan 27. pii: 10.1007/s00415-021-10935.
    >> Share

  118. PAPADOPOULOS D, Gklinos P, Psarros G, Drellia K, et al
    Disease-modifying treatments for multiple sclerosis have not affected the incidence of neoplasms in clinical trials over 3 decades: a meta-analysis with meta-regression.
    J Neurol. 2022 Jan 23. pii: 10.1007/s00415-021-10932.
    >> Share

  119. BERGAMASCHI R, Mallucci G, Fusco S, Montomoli C, et al
    Disability and mortality in a cohort of MS patients: how the real-world scenario is changed.
    J Neurol. 2022 Jan 14. pii: 10.1007/s00415-021-10940.
    >> Share

  120. COBO-CALVO A, Zabalza A, Rio J, Arrambide G, et al
    Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.
    J Neurol. 2022 Jan 10. pii: 10.1007/s00415-021-10958.
    >> Share

  121. CRUZ RA, Varkey T, Flavia A, Samways APA, et al
    Hearing abnormalities in multiple sclerosis: clinical semiology and pathophysiologic mechanisms.
    J Neurol. 2022 Jan 9. pii: 10.1007/s00415-021-10915.
    >> Share

  122. KORSEN M, Pfeuffer S, Rolfes L, Meuth SG, et al
    Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agents.
    J Neurol. 2022 Jan 9. pii: 10.1007/s00415-021-10956.
    >> Share

  123. PROSPERINI L, Tortorella C, Haggiag S, Ruggieri S, et al
    Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies.
    J Neurol. 2022 Jan 4. pii: 10.1007/s00415-021-10951.
    >> Share

  124. BIGAUT K, Kremer L, Fabacher T, Ahle G, et al
    Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.
    J Neurol. 2022 Jan 4. pii: 10.1007/s00415-021-10950.
    >> Share

  125. THOMAS R, Wynford-Thomas R, Robertson NP
    Advances in the use of stem cell transplants in the treatment of multiple sclerosis.
    J Neurol. 2022 Jan 4. pii: 10.1007/s00415-021-10927.
    >> Share

  126. ZRZAVY T, Wielandner A, Haider L, Bartsch S, et al
    FLAIR(2) post-processing: improving MS lesion detection in standard MS imaging protocols.
    J Neurol. 2022;269:461-467.
    >> Share

  127. HELMCHEN C, Buttler GM, Markewitz R, Hummel K, et al
    Acute bilateral optic/chiasm neuritis with longitudinal extensive transverse myelitis in longstanding stable multiple sclerosis following vector-based vaccination against the SARS-CoV-2.
    J Neurol. 2022;269:49-54.
    >> Share

  128. DE LOTT LB, Bennett JL, Costello F
    The changing landscape of optic neuritis: a narrative review.
    J Neurol. 2022;269:111-124.
    >> Share

    November 2021
  129. RIO J, Rovira A, Gasperini C, Tintore M, et al
    Correction to: Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients.
    J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10906.
    >> Share

  130. SRIWASTAVA S, Chaudhary D, Srivastava S, Beard K, et al
    Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature.
    J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10910.
    >> Share

    October 2021
  131. FUCHS TA, Schoonheim MM, Broeders TAA, Hulst HE, et al
    Functional network dynamics and decreased conscientiousness in multiple sclerosis.
    J Neurol. 2021 Oct 29. pii: 10.1007/s00415-021-10860.
    >> Share

  132. WASHINGTON F, Langdon D
    Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review.
    J Neurol. 2021 Oct 21. pii: 10.1007/s00415-021-10850.
    >> Share

  133. ALSCHULER KN, Whibley D, Kratz AL, Jensen MP, et al
    Quality of life in individuals newly diagnosed with multiple sclerosis or clinically isolated syndrome.
    J Neurol. 2021 Oct 19. pii: 10.1007/s00415-021-10842.
    >> Share

  134. BURT RK, Han X, Quigley K, Helenowski IB, et al
    Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis.
    J Neurol. 2021 Oct 11. pii: 10.1007/s00415-021-10820.
    >> Share

  135. FILIPPI M, Danesi R, Derfuss T, Duddy M, et al
    Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis.
    J Neurol. 2021 Oct 9. pii: 10.1007/s00415-021-10836.
    >> Share

  136. PREZIOSA P, Conti L, Rocca MA, Filippi M, et al
    Effects on cognition of DMTs in multiple sclerosis: moving beyond the prevention of inflammatory activity.
    J Neurol. 2021 Oct 7. pii: 10.1007/s00415-021-10832.
    >> Share

  137. RIO J, Rovira A, Gasperini C, Tintore M, et al
    Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients.
    J Neurol. 2021 Oct 1. pii: 10.1007/s00415-021-10823.
    >> Share

  138. JARIUS S, Wilken D, Haas J, Ruprecht K, et al
    Parvovirus B19 and mumps virus antibodies are major constituents of the intrathecal immune response in European patients with MS and increase the diagnostic sensitivity and discriminatory power of the MRZ reaction.
    J Neurol. 2021;268:3758-3765.
    >> Share

    September 2021
  139. PUTHENPARAMPIL M, Perini P, Bergamaschi R, Capobianco M, et al
    Multiple sclerosis epidemiological trends in Italy highlight the environmental risk factors.
    J Neurol. 2021 Sep 27. pii: 10.1007/s00415-021-10782.
    >> Share

  140. PROSPERINI L, Tortorella C, Haggiag S, Ruggieri S, et al
    Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies.
    J Neurol. 2021 Sep 17. pii: 10.1007/s00415-021-10803.
    >> Share

  141. ANDERSEN MA, Buron MD, Magyari M
    Late-onset MS is associated with an increased rate of reaching disability milestones.
    J Neurol. 2021;268:3352-3360.
    >> Share

    August 2021
  142. SUN J, Xie Y, Wang Q, Shen J, et al
    Genes associated with grey matter volume reduction in multiple sclerosis.
    J Neurol. 2021 Aug 29. pii: 10.1007/s00415-021-10777.
    >> Share

  143. BLOCK VJ, Pitsch EA, Gopal A, Zhao C, et al
    Identifying falls remotely in people with multiple sclerosis.
    J Neurol. 2021 Aug 17. pii: 10.1007/s00415-021-10743.
    >> Share

  144. MARGONI M, Preziosa P, Filippi M, Rocca MA, et al
    Anti-CD20 therapies for multiple sclerosis: current status and future perspectives.
    J Neurol. 2021 Aug 11. pii: 10.1007/s00415-021-10744.
    >> Share

  145. ALVINO B, Arianna F, Assunta B, Antonio C, et al
    Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study.
    J Neurol. 2021 Aug 4. pii: 10.1007/s00415-021-10737.
    >> Share

  146. PARDO G, Coates S, Okuda DT
    Outcome measures assisting treatment optimization in multiple sclerosis.
    J Neurol. 2021 Aug 2. pii: 10.1007/s00415-021-10674.
    >> Share

  147. CORTESE R, Prosperini L, Stasolla A, Haggiag S, et al
    Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapy.
    J Neurol. 2021;268:2895-2899.
    >> Share

  148. CILINGIR V, Batur M
    First measured retinal nerve fiber layer thickness in RRMS can be used as a biomarker for the course of the disease: threshold value discussions.
    J Neurol. 2021;268:2858-2865.
    >> Share

    July 2021
  149. FERRARO D, Iaffaldano P, Guerra T, Inglese M, et al
    Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration.
    J Neurol. 2021 Jul 22. pii: 10.1007/s00415-021-10708.
    >> Share

  150. RAUMA I, Mustonen T, Seppa JM, Ukkonen M, et al
    Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients.
    J Neurol. 2021 Jul 13. pii: 10.1007/s00415-021-10664.
    >> Share

  151. NIESSEN A, Schwarz B, Urban M, Kramer S, et al
    Aseptic meningitis after glatiramer acetate.
    J Neurol. 2021;268:2589-2590.
    >> Share

    June 2021
  152. CHISARI CG, Comi G, Filippi M, Paolicelli D, et al
    PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.
    J Neurol. 2021 Jun 28. pii: 10.1007/s00415-021-10676.
    >> Share

  153. SANKARI SE, Van Essche C, van Pesch V
    Cutaneous diseases related to a hyperactive T-cell response in ocrelizumab-treated multiple sclerosis patients.
    J Neurol. 2021 Jun 28. pii: 10.1007/s00415-021-10679.
    >> Share

  154. KOGEL AK, Gold R, Schneider R
    CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient.
    J Neurol. 2021 Jun 27. pii: 10.1007/s00415-021-10661.
    >> Share

  155. S G, S L, C Z, A N, et al
    Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience.
    J Neurol. 2021 Jun 26. pii: 10.1007/s00415-021-10663.
    >> Share

  156. HANNINEN K, Viitala M, Atula S, Laakso SM, et al
    Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study.
    J Neurol. 2021 Jun 25. pii: 10.1007/s00415-021-10673.
    >> Share

  157. HAVLA J, Schultz Y, Zimmermann H, Hohlfeld R, et al
    First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine.
    J Neurol. 2021 Jun 11. pii: 10.1007/s00415-021-10648.
    >> Share

    May 2021
  158. JURYNCZYK M, Klimiec-Moskal E, Kong Y, Hurley S, et al
    Elucidating distinct clinico-radiologic signatures in the borderland between neuromyelitis optica and multiple sclerosis.
    J Neurol. 2021 May 27. pii: 10.1007/s00415-021-10619.
    >> Share

  159. CHEN MH, Chiaravalloti ND, DeLuca J
    Neurological update: cognitive rehabilitation in multiple sclerosis.
    J Neurol. 2021 May 24. pii: 10.1007/s00415-021-10618.
    >> Share

  160. ZRZAVY T, Pfitzner A, Flachenecker P, Rommer P, et al
    Effects of normobaric hypoxic endurance training on fatigue in patients with multiple sclerosis: a randomized prospective pilot study.
    J Neurol. 2021 May 18. pii: 10.1007/s00415-021-10596.
    >> Share

  161. HILDESHEIM FE, Benedict RHB, Zivadinov R, Dwyer MG, et al
    Nucleus basalis of Meynert damage and cognition in patients with multiple sclerosis.
    J Neurol. 2021 May 16. pii: 10.1007/s00415-021-10594.
    >> Share

  162. TOMMASIN S, Cocozza S, Taloni A, Gianni C, et al
    Machine learning classifier to identify clinical and radiological features relevant to disability progression in multiple sclerosis.
    J Neurol. 2021 May 10. pii: 10.1007/s00415-021-10605.
    >> Share

  163. RUGGIERI S, Petracca M, De Giglio L, De Luca F, et al
    A matter of atrophy: differential impact of brain and spine damage on disability worsening in multiple sclerosis.
    J Neurol. 2021 May 3. pii: 10.1007/s00415-021-10576.
    >> Share

    April 2021
  164. GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
    Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry.
    J Neurol. 2021 Apr 22. pii: 10.1007/s00415-021-10559.
    >> Share

  165. COVEY TJ, Golan D, Doniger GM, Sergott R, et al
    Visual evoked potential latency predicts cognitive function in people with multiple sclerosis.
    J Neurol. 2021 Apr 18. pii: 10.1007/s00415-021-10561.
    >> Share

  166. CENTONZE D, Rocca MA, Gasperini C, Kappos L, et al
    Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus.
    J Neurol. 2021 Apr 12. pii: 10.1007/s00415-021-10545.
    >> Share

  167. NYGAARD MKE, Langeskov-Christensen M, Dalgas U, Eskildsen SF, et al
    Cortical diffusion kurtosis imaging and thalamic volume are associated with cognitive and walking performance in relapsing-remitting multiple sclerosis.
    J Neurol. 2021 Apr 7. pii: 10.1007/s00415-021-10543.
    >> Share

    March 2021
  168. MATHEY G, Pische G, Soudant M, Pittion-Vouyovitch S, et al
    Long-term analysis of patients with benign multiple sclerosis: new insights about the disability course.
    J Neurol. 2021 Mar 31. pii: 10.1007/s00415-021-10501.
    >> Share

  169. PINTER D, Kober SE, Fruhwirth V, Berger L, et al
    MRI correlates of cognitive improvement after home-based EEG neurofeedback training in patients with multiple sclerosis: a pilot study.
    J Neurol. 2021 Mar 30. pii: 10.1007/s00415-021-10530.
    >> Share

  170. HJAERESEN S, Sejbaek T, Axelsson M, Vinslov-Jensen H, et al
    The levels of the serine protease HTRA1 in cerebrospinal fluid correlate with progression and disability in multiple sclerosis.
    J Neurol. 2021 Mar 4. pii: 10.1007/s00415-021-10489.
    >> Share

    February 2021
  171. BUCELLO S, Annovazzi P, Ragonese P, Altieri M, et al
    Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.
    J Neurol. 2021 Feb 22. pii: 10.1007/s00415-021-10455.
    >> Share

  172. WALZL D, Solomon AJ, Stone J
    Functional neurological disorder and multiple sclerosis: a systematic review of misdiagnosis and clinical overlap.
    J Neurol. 2021 Feb 21. pii: 10.1007/s00415-021-10436.
    >> Share

  173. CAPONE F, Ferraro E, Motolese F, Di Lazzaro V, et al
    COVID-19 in multiple sclerosis patients treated with dimethyl fumarate.
    J Neurol. 2021 Feb 20. pii: 10.1007/s00415-021-10446.
    >> Share

  174. FILIPPI M, Capra R, Centonze D, Gasperini C, et al
    Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus.
    J Neurol. 2021 Feb 20. pii: 10.1007/s00415-021-10466.
    >> Share

  175. JAKIMOVSKI D, Benedict RHB, Weinstock-Guttman B, Ozel O, et al
    Visual deficits and cognitive assessment of multiple sclerosis: confounder, correlate, or both?
    J Neurol. 2021 Feb 15. pii: 10.1007/s00415-021-10437.
    >> Share

  176. TREABA CA, Herranz E, Barletta VT, Mehndiratta A, et al
    The relevance of multiple sclerosis cortical lesions on cortical thinning and their clinical impact as assessed by 7.0-T MRI.
    J Neurol. 2021 Feb 1. pii: 10.1007/s00415-021-10400.
    >> Share

  177. BERGMAN J, Burman J, Bergenheim T, Svenningsson A, et al
    Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension.
    J Neurol. 2021;268:651-657.
    >> Share

    January 2021
  178. LUCCHINI M, Prosperini L, Buscarinu MC, Centonze D, et al
    Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis.
    J Neurol. 2021 Jan 26. pii: 10.1007/s00415-021-10412.
    >> Share

  179. HARES K, Kemp K, Loveless S, Rice CM, et al
    KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosis.
    J Neurol. 2021 Jan 23. pii: 10.1007/s00415-020-10373.
    >> Share

  180. BOREMALM M, Sundstrom P, Salzer J
    Discontinuation and dose reduction of rituximab in relapsing-remitting multiple sclerosis.
    J Neurol. 2021 Jan 21. pii: 10.1007/s00415-021-10399.
    >> Share

  181. CHISARI CG, Sgarlata E, Arena S, Toscano S, et al
    Rituximab for the treatment of multiple sclerosis: a review.
    J Neurol. 2021 Jan 8. pii: 10.1007/s00415-020-10362.
    >> Share

  182. KEVER A, Buyukturkoglu K, Riley CS, De Jager PL, et al
    Social support is linked to mental health, quality of life, and motor function in multiple sclerosis.
    J Neurol. 2021 Jan 3. pii: 10.1007/s00415-020-10330.
    >> Share

  183. GELIBTER S, Pisa M, Croese T, Dalla Costa G, et al
    Neutrophil-to-lymphocyte ratio: a marker of neuro-inflammation in multiple sclerosis?
    J Neurol. 2021 Jan 3. pii: 10.1007/s00415-020-10322.
    >> Share

  184. ZHUO Z, Li Y, Duan Y, Cao G, et al
    Subtyping relapsing-remitting multiple sclerosis using structural MRI.
    J Neurol. 2021 Jan 2. pii: 10.1007/s00415-020-10376.
    >> Share

  185. WOO MS, Steins D, Haussler V, Kohsar M, et al
    Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients.
    J Neurol. 2021;268:5-7.
    >> Share

    December 2020
  186. NEMA E, Kalina A, Nikolai T, Vyhnalek M, et al
    Correction to: Spatial navigation in early multiple sclerosis: a neglected cognitive marker of the disease?
    J Neurol. 2020 Dec 30. pii: 10.1007/s00415-020-10294.
    >> Share

  187. NEUSS F, von Podewils F, Wang ZI, Susse M, et al
    Epileptic seizures in multiple sclerosis: prevalence, competing causes and diagnostic accuracy.
    J Neurol. 2020 Dec 15. pii: 10.1007/s00415-020-10346.
    >> Share

    November 2020
  188. PREZIOSA P, Rocca MA, Nozzolillo A, Moiola L, et al
    COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience.
    J Neurol. 2020 Nov 20. pii: 10.1007/s00415-020-10309.
    >> Share

    October 2020
  189. SIMONSEN CS, Flemmen HO, Broch L, Brunborg C, et al
    The course of multiple sclerosis rewritten: a Norwegian population-based study on disease demographics and progression.
    J Neurol. 2020 Oct 22. pii: 10.1007/s00415-020-10279.
    >> Share

  190. ZECCA C, Disanto G, Sacco R, MacLachlan S, et al
    Increasing cancer risk over calendar year in people with multiple sclerosis: a case-control study.
    J Neurol. 2020 Oct 21. pii: 10.1007/s00415-020-10170.
    >> Share

  191. ARNETH B
    Contributions of T cells in multiple sclerosis: what do we currently know?
    J Neurol. 2020 Oct 20. pii: 10.1007/s00415-020-10275.
    >> Share

  192. WILLIS MD, Robertson NP
    Multiple sclerosis: early indicators of disease and assessing future risk.
    J Neurol. 2020 Oct 8. pii: 10.1007/s00415-020-10239.
    >> Share

    September 2020
  193. LORSCHEIDER J, Benkert P, Lienert C, Hanni P, et al
    Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis.
    J Neurol. 2020 Sep 24. pii: 10.1007/s00415-020-10226.
    >> Share

    July 2020
  194. CAPUANO R, Altieri M, Bisecco A, d'Ambrosio A, et al
    Psychological consequences of COVID-19 pandemic in Italian MS patients: signs of resilience?
    J Neurol. 2020 Jul 28. pii: 10.1007/s00415-020-10099.
    >> Share

    June 2020
  195. VAN FAALS NL, Dekker I, Balk LJ, Moraal B, et al
    Clinico-radiological dissociation of disease activity in MS patients: frequency and clinical relevance.
    J Neurol. 2020 Jun 20. pii: 10.1007/s00415-020-09991.
    >> Share

  196. PATTI F, Zimatore GB, Brescia Morra V, Aguglia U, et al
    Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study.
    J Neurol. 2020;267:1812-1823.
    >> Share

  197. CAROTENUTO A, Costabile T, De Lucia M, Moccia M, et al
    Predictors of Nabiximols (Sativex((R))) discontinuation over long-term follow-up: a real-life study.
    J Neurol. 2020;267:1737-1743.
    >> Share

    January 2020
  198. FREEDMAN MS, Brod S, Singer BA, Cohen BA, et al
    Clinical and MRI efficacy of sc IFN beta-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS.
    J Neurol. 2020;267:64-75.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016